MNK - Mallinckrodt Public Limited Company

NYSE - NYSE Delayed Price. Currency in USD
13.52
+0.17 (+1.27%)
At close: 4:01PM EDT

13.52 0.00 (0.00%)
After hours: 5:47PM EDT

Stock chart is not supported by your current browser
Previous Close13.35
Open13.38
Bid0.00 x 0
Ask0.00 x 0
Day's Range13.31 - 13.68
52 Week Range13.05 - 49.12
Volume1,680,871
Avg. Volume4,044,677
Market Cap1.168B
Beta1.19
PE Ratio (TTM)0.62
EPS (TTM)21.80
Earnings DateMay 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.76
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    Mallinckrodt To Present At UBS Global Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom , April 20, 2018 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, May 22, 2018 ...

  • Reuters9 days ago

    U.S. drug agency proposes rules to rein in opioid manufacturing

    The U.S. government on Tuesday proposed tightening rules governing the amount of prescription opioid painkillers that drugmakers can manufacture in a given year, in hopes of reining in the deadly opioid epidemic. The Drug Enforcement Administration's proposed changes to its regulations over addictive drug manufacturing quotas were announced by Attorney General Jeff Sessions. The plan could sharply reduce the annual production of painkillers.

  • PR Newswire10 days ago

    Mallinckrodt plc Announces $300 Million Debt Repayment

    -- Company repays debt maturing April 2018 with cash on hand -- STAINES-UPON-THAMES, United Kingdom , April 16, 2018 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical ...

  • CNBC14 days ago

    Mallinckrodt shares slide on whistleblower lawsuit involving its best-selling drug

    The lawsuit claims Mallinckrodt continued to raise the price of Acthar despite knowing what was in it.

  • Novartis and Other Drug Stocks With FDA Catalysts in April
    Zacks17 days ago

    Novartis and Other Drug Stocks With FDA Catalysts in April

    With just a quarter gone by this year, the FDA has already granted approval to six new treatments.

  • PR Newswire18 days ago

    Mallinckrodt To Present At Deutsche Bank's 43rd Annual Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom , April 9, 2018 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, May 9, 2018, ...

  • PR Newswire23 days ago

    Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors

    STAINES-UPON-THAMES, United Kingdom, April 4, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced it has nominated two new members for its Board of Directors. Both Paul R. Carter and Anne C. Whitaker have extensive experience in the branded pharmaceutical industry and will join the Mallinckrodt Board pending shareholder vote at the Annual General Meeting in May, 2018. For more than 25 years, Mr. Carter, age 57, has held a variety of leadership roles in the biopharmaceutical industry, serving as executive vice president, commercial operations of Gilead Sciences, Inc. from 2014 to 2016, and senior vice president and head, international commercial operations from 2006 to 2014.

  • PR Newswire23 days ago

    Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018

    STAINES-UPON-THAMES, United Kingdom, April 4, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced that Angus Russell will succeed Melvin Booth as non-executive chairman of the Company's Board of Directors when Mr. Booth retires from the Board in May 2018. A director, member of the Audit and Portfolio Committees and chairman of the Mallinckrodt Board since June 2013, Mr. Booth, age 73, has elected to retire. Commenting on his decision, Mr. Booth said, "It has been a tremendous privilege to serve on the Mallinckrodt Board of Directors since the company became public in 2013, and a particular honor to serve as chairman.

  • PR Newswirelast month

    Mallinckrodt plc To Report Earnings Results For The First Quarter Of Fiscal 2018

    Callers will need to provide the Conference ID of 2886785. All callers will be required to provide the Conference ID of 2886785. Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies.

  • Baxter International Completes Its Mallinckrodt Assets Buy
    Market Realistlast month

    Baxter International Completes Its Mallinckrodt Assets Buy

    Baxter International (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt Pharmaceuticals (MNK) for a total consideration of $185.0 million. This transaction includes $153.0 million in upfront payments and the rest in future milestone-based payments. Additionally, Baxter International has assumed Preveleak’s associated expenses and the contingent liabilities. Preveleak’s manufacturing operations are also included in the deal.

  • ACCESSWIRElast month

    Mallinckrodt, Upcoming PDUFA Date, Analysts Review and Target, and Potential Catalysts

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...

  • PR Newswirelast month

    Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation

    Mallinckrodt plc (MNK), a leading specialty pharmaceutical company, today announced the inaugural recipient of its Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award. The winning entry was submitted by investigator Dr. Nick Matthews and co-investigator Dr. Arun Alfred of the Department of Haematology at Rotherham NHS Foundation Trust in the United Kingdom.

  • CNBClast month

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • PR Newswirelast month

    Mallinckrodt Completes Sale Of RECOTHROM® And PREVELEAK® To Baxter

    STAINES-UPON-THAMES, United Kingdom, March 19, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading specialty pharmaceutical company, announced today it has closed the sale of RECOTHROM® Thrombin topical (Recombinant) and PREVELEAK® Surgical Sealant to Baxter International Inc. (BAX). "This action further illustrates the strategic evolution of our portfolio, and will free resources for investing in treatments for seriously ill infants and adults," said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. The approximately $185 million transaction consists of a base payment of $153 million, inclusive of existing inventory and subject to a closing inventory adjustment, and the remainder in potential future milestones.

  • PR Newswirelast month

    Mallinckrodt Recognized as Manufacturing Leadership Awards 2018 Winner

    STAINES-UPON-THAMES, United Kingdom, March 15, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading specialty pharmaceutical company, announced today it has been recognized as a Frost & Sullivan Manufacturing Leadership Award winner for its outstanding achievement in three categories – Operational Excellence Leadership, Supply Chain Leadership and Sustainability Leadership. The company's Hobart, N.Y., manufacturing site earned all three awards through its highly successful implementation of key two-year initiatives designed to enhance multiple aspects of its manufacturing operations.

  • This News Explains Mallinckrodt's Fall Today
    Motley Fool2 months ago

    This News Explains Mallinckrodt's Fall Today

    Investors are fleeing after SEC filings reveal that the company has received a grand jury subpoena.

  • Mallinckrodt PLC (MNK) Jumps: Stock Rises 15.3%
    Zacks2 months ago

    Mallinckrodt PLC (MNK) Jumps: Stock Rises 15.3%

    Mallinckrodt PLC (MNK) shares rose more than 15% in the last trading session, amid huge volumes.

  • Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4
    Zacks2 months ago

    Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4

    Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MNK earnings conference call or presentation 27-Feb-18 1:30pm GMT

    Q4 2017 Mallinckrodt Plc Earnings Call

  • Reuters2 months ago

    U.S. subpoenas Mallinckrodt for information on opioid painkillers

    Pharmaceutical company Mallinckrodt Plc said on Tuesday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to generic drugs it produces that contain the opioid painkiller oxymorphone. The drugmaker disclosed in a U.S. Securities and Exchange Commission filing that it received a subpoena on Jan. 27 seeking documents related to the company's distribution, marketing and sale of oxymorphone generic products. The subpoena came from the U.S. Attorney's Office for the Southern District of Florida.

  • Why Mallinckrodt, Tenet Healthcare, and AES Jumped Today
    Motley Fool2 months ago

    Why Mallinckrodt, Tenet Healthcare, and AES Jumped Today

    Find out how these stocks bucked a tough market.

  • GuruFocus.com2 months ago

    US Markets Surge on Tuesday

    Mallinckrodt beat street estimates

  • MarketWatch2 months ago

    Mallinckrodt's stock soars to pace NYSE gainers after profit and revenue beat

    Shares of Mallinckrodt PLC soared 24% in early trade Tuesday, enough to make them the biggest gainer on the NYSE, after the specialty drug maker beat profit and revenue expectations. The company swung ...

  • Associated Press2 months ago

    Mallinckrodt beats Street 4Q forecasts

    On a per-share basis, the Surrey, Britain-based company said it had net income of $17.41. Earnings, adjusted for one-time gains and costs, were $2.01 per share. The results exceeded Wall Street expectations. ...